Capital Markets Day 2026
The event will provide investors with a deeper understanding of hVIVO's strategic evolution from a specialist human challenge trial provider into a differentiated, integrated early clinical ...
The event will provide investors with a deeper understanding of hVIVO's strategic evolution from a specialist human challenge trial provider into a differentiated, integrated early clinical development partner, supporting biotechnology and pharmaceutical companies from preclinical strategy through first-in-human studies, patient trials and specialist laboratory services.
Through presentations from clients, investors, industry experts and hVIVO leadership, the event will explore how the Company's end-to-end platform is helping sponsors generate high-quality data earlier, accelerate development timelines and reduce execution risk across the clinical development pathway.
The programme will feature real-world case studies, including on hVIVO's role in supporting Cidara Therapeutics' drug development strategy leading to a $9 billion exit, and a presentation from ILiAD Biotechnologies on the world's first Phase III pivotal human challenge trial.
Discussions will also explore emerging investment trends in infectious disease, the strategic value of human challenge trials, the increasing importance of specialist partners in early drug development across Big Pharma and biotech, and how hVIVO's integrated platform supports faster, more informed development decisions.
External speakers will include:
- Mario Barro - PhD, Head of Infectious Diseases, RA Capital
- Stephanie Noviello - Chief Medical Officer, ILiAD Biotechnologies
- Corrina Pavetto - ClinReg Consulting, LLC (formerly SVP Clinical Development, Cidara Therapeutics)
- Konstantinos Sinogiannis - Global Category Manager, Boehringer Ingelheim
- Rick Pierce - Chief Executive Officer, Decoy Therapeutics
- Professor Richard Russell - Head of Immunobiology, Professor of Respiratory Medicine, King's College London
- Dr Diane Gbesemete - Clinical Research Fellow, University Hospital Southampton
The event will conclude with the opportunity for attendees to tour hVIVO's Canary Wharf quarantine facility and laboratories.
Analysts, institutional investors and media are welcome to attend the event in-person. Due to capacity constraints, attendance will be limited, however, a recording of the presentation will be made available on the Company's website shortly after the event.
To register your interest for the Capital Markets Day, please email hVIVO@icrhealthcare.com.
You might be interested in...
View all
SaxoCell Conference on Cell and Gene Therapy
Explore the Future of Cell and Gene Therapy Development hVIVO will be attending the SaxoCell Conference, a focused ...
11th German Pharm-Tox Summit 2026
The GPTS is organized by the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT). The ...
BIO International Convention
hVIVO is proud to be attending BIO International Convention 2026, the world’s largest gathering of biotechnology, ...
World Vaccine Congress Europe
Accelerate Vaccine Development Through Collaboration and Innovation hVIVO will be attending the World Vaccine Congress ...
BIO-Europe 2026
Connect with the Right Partners to Accelerate Biopharma Growth hVIVO will be attending BIO-Europe, the leading ...
Dutch Life Sciences Conference 2026
Connect with Europe’s Leading Life Sciences Ecosystem hVIVO will be attending the Dutch Life Sciences Conference, a key ...